Method for analyzing and identifying intestinal flora and application of intestinal flora to treatment of nontuberculous mycobacterial diseases

Through the intestinal flora analysis and identification method, it was found that the Blautia obeum flora is beneficial to combat non-tuberculous mycobacterium, which solved the problem of poor efficacy in treating non-tuberculous mycobacterium lung disease in the prior art, and provided a more effective and economical Treatment options reduce the recurrence and severity of the disease.

CN118957108APending Publication Date: 2024-11-15SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411053903.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art methods for treating non-tuberculous mycobacterium lung disease are poorly effective, have high cost and have great side effects, and lack the application of intestinal flora in the treatment.

Method used

A method of intestinal microbiota analysis and identification, including DNA extraction, PCR amplification, Pooling and gel purification, library construction and sequencing, data analysis and other steps, through OTU clustering, species annotation, diversity analysis and network analysis, The Blautia obeum bacteria were found to be beneficial against non-tuberculous mycobacteria and were used to develop probiotic products to treat the disease.

Benefits of technology

By increasing the intestinal flora, a more effective, cheap and less side effects treatment plan is provided, which enhances resistance to non-tuberculous mycobacterium infection and reduces recurrence rates and severity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957108A_ABST
    Figure CN118957108A_ABST
Patent Text Reader

Abstract

The invention discloses an analysis and identification method of intestinal flora and application of the intestinal flora to treatment of nontuberculous mycobacterium diseases, and relates to the technical field of intestinal microorganisms, and by analyzing and identifying the intestinal flora of healthy people and nontuberculous mycobacterium disease patients, it is found that Blauria-egg Blauria is helpful for enhancing the resistance to nontuberculous mycobacterium infection, and the Blauria-egg Blauria is helpful for enhancing the resistance to nontuberculous mycobacterium infection. A mouse experiment further verifies that the intestinal flora can be used for treating nontuberculous mycobacterium diseases. The method for analyzing and identifying the intestinal flora can promote the development of new probiotic products, and the way of increasing the intestinal flora replaces complex and expensive antibiotics with high side effects and poor treatment effects to be combined with the antibiotics for treating the nontuberculous mycobacterium lung diseases; the medicine which is more effective, low in price and few in side effect is provided for treatment of the nontuberculosis mycobacterium lung disease, and the recurrence rate and the severity of the nontuberculosis mycobacterium lung disease are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of intestinal microorganisms, and in particular relates to an analysis and identification method of intestinal flora and a use thereof in treating nontuberculous mycobacterial diseases. Background Art

[0002] Non-tuberculosis mycobacteria (NTM) refer to mycobacteria other than the Mycobacterium tuberculosis complex and Mycobacterium leprae. Nearly 200 species have been identified so far. These previously unknown "relatives" of tuberculosis were once considered harmless environmental microorganisms, posing a threat only to individuals with defective lung structures or immunosuppression. However, the increasing infection rate year by year proves that they are infecting children and adults with normal immunity. In developed countries, the incidence of non-tuberculosis mycobacteria has exceeded that of tuberculosis (TB). However, due to the slow growth rate of non-tuberculosis mycobacteria and their natural resistance to commonly used antibiotics, treatment usually requires a combination of at least 3 antibiotics and a treatment time of at least 12 months (continued for 12 months after turning negative), which means expensive drug costs and unbearable drug side effects. Worse still is the low success rate of treatment, high relapse rate, and poor prognosis, with a five-year mortality rate that may exceed 30%. Therefore, we urgently need to develop good prevention and treatment policies, and a deeper understanding of the interaction between host and pathogen is crucial.

[0003] Since 70-80% of immune cells are present in the intestine, there is an intricate interaction between the intestinal microbiota, the intestinal epithelium, and the local mucosal immune system. With the advancement of high-throughput sequencing technology, research on the connection between the human microbiota and chronic respiratory diseases has attracted increasing attention. Emerging evidence shows that there is a cross-kingdom interaction between the intestinal microbiota and the lungs, which is hypothesized to be the "gut-lung axis" by changing the immune response and the interaction between microbiota in different parts.

[0004] Existing studies on the association between intestinal flora and lung diseases mainly focus on diseases such as asthma and COPD, and there are fewer studies on the correlation between intestinal flora and lung infectious diseases. In the prior art, there is no method for treating non-tuberculous mycobacterial lung diseases by increasing intestinal flora. The present invention provides more feasibility for clinical treatment of non-tuberculous mycobacterial diseases through an intestinal flora, and can provide new ideas for treating non-tuberculous mycobacterial lung diseases. Summary of the invention

[0005] The purpose of the present invention is to provide an intestinal flora for treating non-tuberculous mycobacterium lung disease, so as to solve the technical problem of good effect and low cost in the prior art for treating non-tuberculous mycobacterium lung disease.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A method for analyzing and identifying intestinal flora, the method comprising the following steps:

[0008] (1) Extract DNA from stool samples;

[0009] (2) PCR amplification and product electrophoresis detection: PCR amplification is performed using genomic DNA as a template; the fragment length of the PCR product is detected;

[0010] (3) Pooling and gel purification: Determine the concentration of PCR products and mix the PCR products;

[0011] (4) Library construction and sequencing: follow the steps of starting DNA quality control and purification, end repair and end A addition, adapter ligation and cleaning, nuclease treatment and cleaning, total mass calculation, library concentration quantification and sequencing;

[0012] (5) Performing data analysis on the stool samples, including the following steps:

[0013] Step 1: OTU clustering and species annotation;

[0014] Step 2: Species composition analysis;

[0015] Step 3: Alpha diversity analysis;

[0016] Step 4: Beta diversity analysis;

[0017] Step 5: Analysis of differences among sample groups;

[0018] Step 6: Species interaction network analysis.

[0019] Furthermore, in the step (1) of the method for analyzing and identifying intestinal flora, 0.1-0.2 g of fecal sample is taken into a centrifuge tube, 220 μL of Buffer STE, 30 μL of Lysozyme and 5 μL of RNase Solution are added thereto, the bacteria are fully resuspended by vortexing, and the mixture is incubated at 37°C for 30-40 minutes; 20 μL of Proteinase K and 250 μL of Buffer MBL are added to the lysate, the mixture is fully inverted and vortexed for 15-20 seconds, and the mixture is incubated at 70°C for 10-15 minutes; 250 μL of anhydrous ethanol is added to the lysate or supernatant; the mixture is vortexed; the gDNA Extraction Mini Columns are loaded into a 2 ml Collection Tube, and the supernatant is transferred to the column; the mixture is centrifuged at 10,000 g for 1 minute; the filtrate is discarded, and the column is loaded back into the collection tube; 500 μL of Buffer D diluted with anhydrous ethanol is added; Add Buffer W1A to the column; centrifuge at 10,000 g for 30 seconds; discard the filtrate and put the column back into the collection tube; add 600 μL of Buffer W2A diluted with anhydrous ethanol to the column, centrifuge at 10,000 g for 30 seconds, discard the filtrate, put the column back into the collection tube, and repeat the washing twice; centrifuge the empty column at 13,000 g for 2 minutes; transfer the column to a new 1.5 ml centrifuge tube, add 50-100 μL Buffer EB to the center of the column membrane; let it stand at room temperature for 2-5 minutes, and centrifuge at 13,000 g for 1 minute to obtain genomic DNA; use Thermo NanoDrop One to detect the integrity, purity and concentration of the DNA.

[0020] Furthermore, in the step (2) of PCR amplification and product electrophoresis detection of the intestinal flora analysis and identification method, PCR amplification is performed using specific primers with barcodes, and the primers correspond to the regions, and the primers for the 16S V1-V9 region are shown in Table 1:

[0021] Table 1

[0022] 27F 5'-AGRGTTYGATYMTGGCTCAG-3' 1492R 5'-RGYTACCTTGTTACGACTT-3'

[0023] The PCR reaction system is shown in Table 2:

[0024] Table 2

[0025] Reagent name dose Q5 25μL Primer-F 10μM 5μL Primer-R 10μM 5μL DNA 2.5-50ng No nucleic acid contamination water Add to 50 μL

[0026] PCR reaction conditions are shown in Table 3:

[0027] Table 3

[0028]

[0029] Furthermore, in the step (2) of PCR amplification and product electrophoresis detection of the intestinal flora analysis and identification method, the PCR of each sample is repeated 3 times, and the PCR products of the same sample are mixed; and the fragment length of the PCR product is detected by 1-2% agarose gel electrophoresis.

[0030] Furthermore, in step (3) of the intestinal flora analysis and identification method, GeneTools Analysis Software, Version 4.03.05.0, SynGene is used to compare the concentrations of PCR products in pooling and gel purification; the volume of each sample is calculated according to the principle of equal mass to mix each PCR product; the HiPure Gel Pure DNA Mini Kit produced by Shanghai Maigen Biotechnology Co., Ltd. is used to recover the PCR mixed product, and the target DNA fragment is eluted with TE buffer.

[0031] Furthermore, the operations in step (4) of library construction and sequencing of the intestinal flora analysis and identification method are as follows:

[0032] Quality control and cleanup of starting DNA: Before library construction, evaluate the quantity and size distribution of starting DNA, measure the DNA concentration of each sample using a Qubit fluorometer, and clean it using 1.3X SMRTbell clean magnetic columns;

[0033] End repair and end addition A: transfer to a new microcentrifuge tube, add 46 μL sample and then add 8 μL repair buffer, 4 μL end repair mixture, 2 μL DNA repair mixture, vortex to mix, centrifuge in a microcentrifuge to collect the liquid and set the program to run;

[0034] Connector connection and cleaning: first add the adapter solution, then add the connection mixture and connection enhancer in sequence, vortex mix, centrifuge to collect the liquid, set the program to run, use SMRTbell purification beads to wash after the run, and take the supernatant;

[0035] Nuclease treatment and cleaning: add nuclease buffer and nuclease mixture in sequence, vortex mix, centrifuge to collect liquid, set the program to run, use SMRTbell purification beads for cleaning after the run, and take the supernatant;

[0036] Calculate total mass: Take a 1 μL aliquot from each tube and dilute with 9 μL elution buffer or water. Measure DNA using a Qubit fluorometer.

[0037] Library concentration quantification: Library construction is completed after the 16S amplicons are pooled and concentrated;

[0038] Sequencing: The constructed 16S amplicon library was sequenced using the PacBio Sequel II platform.

[0039] Furthermore, in the step (4) of library construction and sequencing of the intestinal flora analysis and identification method, end repair and end A addition, a 60 μL system is configured, 46 μL of sample, 8 μL of repair buffer, 4 μL of end repair mixture and 2 μL of DNA repair mixture are added, and the setting program is shown in Table 4:

[0040] Table 4

[0041] step time temperature 1 30 minutes 37℃ 2 5 minutes 65℃ 3 Keep 4℃

[0042] When connecting and cleaning the connector, first add 4 μL of SMRTbell adapter solution, then add 30 μL of connection mixture and 1 μL of connection enhancer in sequence. The operation setting program is shown in Table 5:

[0043] Table 5

[0044] step time temperature 1 30 minutes 20℃ 2 Keep 4℃

[0045] During nuclease treatment and washing, add 5 μL of nuclease buffer and 5 μL of nuclease mixture. The setting program is shown in Table 6:

[0046] Table 6

[0047] step time temperature 1 15 minutes 37℃ 2 Keep 4℃ .

[0048] Furthermore, in the fecal sample data analysis of step (5) of the intestinal flora analysis and identification method, the operation steps are as follows:

[0049] Step 1: OTU clustering and species annotation

[0050] OTU clustering: All Clean Tags of all samples were clustered using usearch software. By default, the sequences were clustered into OTUs (Operational Taxonomic Units) with a consistency of 97%. It was assumed that one OTU represented one species, and the sequence with the highest frequency was used as the representative sequence of each OTU for subsequent annotation.

[0051] Chimera singleton removal: remove chimera and singleton sequences during clustering;

[0052] Representative sequence species annotation: The assign_taxonomy.py script in Qiime was used to compare the representative sequence of each OTU after removing chimeras and singletons with the Silva database using RDP Classifier to obtain species annotation information;

[0053] Step 2: Species composition analysis

[0054] R software was used to calculate the relative abundance of species at the phylum, class, order, family, genus, and species levels; KRONA software was used to visualize the species annotation results of a single sample, and GraPhlAn software was used to obtain a single sample OTU annotation circle map based on GraPhlAn;

[0055] Step 3: Alpha diversity analysis

[0056] Alpha diversity index statistics: Based on the OTU abundance table, QIIME v1.9.1 was used to calculate six diversity indices: chao1, PD_whole_tree, observed_species, Shannon, Simpson, and dominance;

[0057] Rarefaction curve: Based on the OTU abundance table, QIIME v1.9.1 was used to calculate the rarefaction curves of eight diversity indices, including chao1, PD_whole_tree, observed_species, Shannon, Simpson, dominance, Good's coverage, and Faith's PD.

[0058] Rank Abundance curve: Rank Abundance calculation based on OTU abundance table;

[0059] Step 4: Beta diversity analysis

[0060] Bray-Curtis, Weighted Unifrac, and Unweighted Unifrac distances were calculated based on the OTU abundance information of the samples. Based on the above distance matrix, NMDS non-metric multidimensional scaling analysis, PCoA principal coordinate analysis, and UPGMA non-weighted group average cluster analysis were performed;

[0061] Sample distance heatmap analysis: The vegan software of R software was used to combine the Bray-Curtis, WeightedUnifrac and Unweighted Unifrac distance algorithms and the hclust function for heatmap cluster analysis;

[0062] Cluster analysis: Based on the OTU abundance table and the beta diversity distance matrix, the UPGMA—Unweighted Pair-group Method with Arithmetic Mean cluster analysis method was used to construct a cluster tree of the samples;

[0063] Step 5: Analysis of differences between sample groups

[0064] Significance analysis of community structure differences among groups: Anosim, MRPP, Adonis and Amova were performed using the anosim function, mrpp function, adonis function and Amova of the R software vegan and pegas packages;

[0065] LEfSe analysis: Based on the homogenized abundance table OTU_table of each species level, LEfse software was used to perform significant difference analysis of species between groups. First, non-parametric factorial Kruskal-Wallis sum-rank test was used for detection, then grouped Wilcoxon rank sum test was used, and finally linear discriminant analysis LDA was used, that is, LDA Score. The screening value of LDA Score was set to 2 for difference analysis between sample groups.

[0066] Step 6: Species Interaction Network Analysis

[0067] Collinearity network analysis: Based on the OTU abundance table, R software was used to perform collinearity network analysis on the species abundance information among different samples.

[0068] Furthermore, the intestinal flora analysis and identification method is used in the treatment of non-tuberculous mycobacterial diseases.

[0069] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0070] 1. The present invention finds that Blautia obeum intestinal flora helps to enhance resistance to nontuberculous mycobacterial infection through analysis and identification of intestinal flora and clinical follow-up investigation, which can promote the development of new probiotic products, especially products containing or promoting the growth of Blautia obeum, for the prevention or treatment of nontuberculous mycobacterial disease infection.

[0071] 2. The present invention replaces the complex, expensive, high-side-effect, and poor-treatment antibiotic combination regimen with intestinal flora, and treats non-tuberculous mycobacterial lung disease by increasing intestinal flora, thereby providing a more effective, low-cost, and less-side-effect drug for the treatment of non-tuberculous mycobacterial lung disease, and reducing the recurrence rate and severity of non-tuberculous mycobacterial lung disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0073] Figure 1 A PCR electrophoresis gel diagram provided by an embodiment of the present invention, wherein M is an electrophoresis marker, and CK represents a blank control group;

[0074] Figure 2 The intestinal flora analysis results provided by the embodiments of the present invention;

[0075] Figure 3 The changes of differential bacterial species during the follow-up process provided by the embodiment of the present invention, wherein HC represents a healthy control group, F1 represents a patient with non-tuberculous mycobacterium disease in the first follow-up, F2 represents a patient with non-tuberculous mycobacterium disease in the second follow-up, and F3 represents a patient with non-tuberculous mycobacterium disease in the third follow-up;

[0076] Figure 4 The damage of mouse lung tissue under different treatment methods provided in the embodiments of the present invention. DETAILED DESCRIPTION

[0077] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0078] Example 1

[0079] The present invention provides an analysis and identification method of intestinal flora and use thereof for treating non-tuberculous mycobacterial disease. Stool samples of 80 patients with non-tuberculous mycobacterial disease and 20 healthy controls from Shanghai Pulmonary Hospital are collected, and the patients are divided into a disease progression group and a stable group. All the collected stool samples are analyzed. The method comprises the following steps:

[0080] (1) DNA extraction from fecal samples

[0081] DNA from fecal samples was extracted using a bacterial DNA rapid extraction kit produced by Ark Biosafety Technology Co., Ltd. 0.1 g of fecal sample was added to a centrifuge tube, 220 μL of Buffer STE, 30 μL of Lysozyme and 5 μL of RNase Solution were added, the bacteria were fully resuspended by vortexing, and the mixture was incubated at 37°C for 30 minutes; 20 μL of Proteinase K and 250 μL of Buffer MBL were added to the lysate, the mixture was fully inverted and vortexed, and the mixture was incubated at 70°C for 10 minutes; 250 μL of anhydrous ethanol was added to the lysate or supernatant; the mixture was vortexed for 15 seconds; the gDNA Extraction Mini Columns were loaded into a 2 ml Collection Tube, and the supernatant was transferred to the column; the column was centrifuged at 10,000 g for 1 minute; the filtrate was discarded, and the column was loaded back into the collection tube; 500 μL of Buffer diluted with anhydrous ethanol was added Add Buffer W1A to the column; centrifuge at 10,000 g for 30 seconds; discard the filtrate and put the column back into the collection tube; add 600 μL of Buffer W2A diluted with anhydrous ethanol to the column, centrifuge at 10,000 g for 30 seconds, discard the filtrate, put the column back into the collection tube, and repeat the washing twice; centrifuge the empty column at 13,000 g for 2 minutes; transfer the column to a new 1.5 ml centrifuge tube, add 50-100 μL Buffer EB to the center of the column membrane; leave at room temperature for 2 minutes, centrifuge at 13,000 g for 1 minute to obtain genomic DNA; use Thermo NanoDrop One to detect the integrity, purity and concentration of the DNA.

[0082] (2) PCR amplification and product electrophoresis detection

[0083] Using genomic DNA as a template, PCR amplification was performed using specific primers with barcodes. The primers corresponded to the region. The primers for the 16SV1-V9 region are shown in Table 1:

[0084] Table 1

[0085] 27F 5'-AGRGTTYGATYMTGGCTCAG-3' 1492R 5'-RGYTACCTTGTTACGACTT-3'

[0086] The PCR reaction system is shown in Table 2:

[0087] Table 2

[0088] Reagent name dose Q5 25μL Primer-F (10 μM) 5μL Primer-R (10 μM) 5μL DNA 2.5-50ng No nucleic acid contamination water Add to 50 μL

[0089] PCR reaction conditions are shown in Table 3:

[0090] Table 3

[0091]

[0092]

[0093] The PCR of each sample was repeated three times, and the PCR products of the same sample were mixed; the fragment length of the PCR product was detected by 1-2% agarose gel electrophoresis; the fragment length and concentration of the PCR product were detected, such as Figure 1 As shown, M is the electrophoresis marker, CK represents the blank control group, and all markers used were purchased from Shanghai Sangon Biotechnology Co., Ltd.

[0094] (3) Pooling and gel cutting and purification

[0095] GeneTools Analysis Software, Version 4.03.05.0, SynGene was used to compare the concentrations of PCR products. The volume of each sample was calculated according to the principle of equal mass to mix the PCR products. The HiPure Gel Pure DNA Mini Kit produced by Shanghai Maigen Biotechnology Co., Ltd. was used to recover the PCR mixed product, and the target DNA fragment was eluted with TE buffer.

[0096] (4) Library construction and sequencing

[0097] Quality control and purification of starting DNA: Before library construction, the DNA concentration was measured using a Qubit fluorometer to assess the quantity and size distribution of the starting DNA, the DNA concentration of each sample was measured, and the cleaning was performed using a 1.3X SMRTbell magnetic column;

[0098] End repair and end addition A: Transfer to a new microcentrifuge tube, add 46 μL of sample, then add 8 μL of repair buffer, 4 μL of end repair mixture, and 2 μL of DNA repair mixture in sequence, vortex to mix, centrifuge in a microcentrifuge to collect the liquid, and set the program to run. The program is shown in Table 4:

[0099] Table 4

[0100] step time temperature 1 30 minutes 37℃ 2 5 minutes 65℃ 3 Keep 4℃

[0101] Connector connection and cleaning: first add 4μL SMRTbell adapter solution, then add 30μL connection mixture and 1μL connection enhancer in sequence, vortex mix, centrifuge to collect the liquid, set the program to run, use SMRTbell purification beads to clean after the run, and take the supernatant; the connection operation setting program is shown in Table 5:

[0102] Table 5

[0103] step time temperature 1 30 minutes 20℃ 2 Keep 4℃

[0104] Nuclease treatment and cleaning: add 5 μL of nuclease buffer and 5 μL of nuclease mixture in sequence, vortex and mix, centrifuge and collect the liquid, set the program to run, clean after the run, and take the supernatant; the nuclease treatment setting program is shown in Table 6:

[0105] Table 6

[0106] step time temperature 1 15 minutes 37℃ 2 Keep 4℃

[0107] Calculate total mass: Take a 1 μL aliquot from each tube and dilute with 9 μL elution buffer or water. Measure DNA using a Qubit fluorometer.

[0108] Library concentration quantification: Library construction is completed after the 16S amplicons are pooled and concentrated;

[0109] Sequencing: The constructed 16S amplicon library was sequenced using the PacBio Sequel II platform.

[0110] (5) Performing data analysis on the stool samples, including the following steps:

[0111] Step 1: OTU clustering and species annotation

[0112] OTU clustering: All Clean Tags of all samples were clustered using usearch software. By default, the sequences were clustered into OTUs (Operational Taxonomic Units) with a consistency of 97%, and one OTU was considered to represent one species. The sequence with the highest frequency of occurrence was used as the representative sequence of each OTU for subsequent annotation.

[0113] Chimera and singleton removal: remove chimera and singleton sequences during clustering.

[0114] Representative sequence species annotation: The assign_taxonomy.py script in Qiime was used to compare the representative sequence of each OTU after removing chimeras and singletons with the Silva database using RDP Classifier to obtain species annotation information.

[0115] Step 2: Species composition analysis

[0116] R software was used to count the relative abundance of species at the phylum, class, order, family, genus, and species levels. KRONA software was used to visualize the species annotation results of a single sample, and GraPhlAn software was used to obtain a single sample OTU annotation circle diagram based on GraPhlAn.

[0117] Step 3: Alpha diversity analysis

[0118] Alpha diversity index statistics: Based on the OTU abundance table, QIIME (v1.9.1) was used to calculate six diversity indices: chao1, PD_whole_tree, observed_species, Shannon, Simpson, and dominance.

[0119] Rarefaction curve: Based on the OTU abundance table, QIIME (v1.9.1) was used to calculate the rarefaction curves of eight diversity indices, including chao1, PD_whole_tree, observed_species, Shannon, Simpson, dominance, Good's coverage, and Faith's PD.

[0120] Rank Abundance curve: Rank Abundance calculation is performed based on the OTU abundance table.

[0121] Step 4: Beta diversity analysis

[0122] The Bray-Curtis, Weighted Unifrac and Unweighted Unifrac distances were calculated according to the OTU abundance information of the samples. Based on the above distance matrix, NMDS non-metric multidimensional scaling analysis, PCoA principal coordinate analysis and UPGMA non-weighted group average cluster analysis were performed.

[0123] Sample distance heatmap analysis: The vegan software of R software was used to combine the Bray-Curtis, WeightedUnifrac and Unweighted Unifrac distance algorithms and the hclust function for heatmap cluster analysis;

[0124] Cluster analysis: Based on the OTU abundance table and the beta diversity distance matrix, the UPGMA—Unweighted Pair-group Method with Arithmetic Mean cluster analysis method was used to construct a cluster tree of the samples.

[0125] Step 5: Analysis of differences between sample groups

[0126] Significance analysis of community structure differences among groups: Anosim, MRPP, Adonis and Amova were performed using the anosim function, mrpp function, adonis function and Amova of the R software vegan and pegas packages.

[0127] LEfSe analysis: Based on the homogenized abundance table OTU_table of each species level, LEfse software was used to perform significant difference analysis of species between groups. First, the non-parametric factorial Kruskal-Wallis sum-rank test was used, then the grouped Wilcoxon rank sum test was used, and finally the linear discriminant analysis LDA was used, that is, LDA Score, and the screening value of LDA Score was set to 2.

[0128] Step 6: Species Interaction Network Analysis

[0129] Collinearity network analysis: Based on the OTU abundance table, R software was used to perform collinearity network analysis on the species abundance information among different samples.

[0130] Example 2

[0131] The present invention provides an analysis and identification method of intestinal flora and use thereof for treating non-tuberculous mycobacterial disease. Stool samples of 80 patients with non-tuberculous mycobacterial disease and 20 healthy controls from Shanghai Pulmonary Hospital are collected, and the patients are divided into a disease progression group and a stable group. All the collected stool samples are analyzed. The method comprises the following steps:

[0132] (1) DNA extraction from fecal samples

[0133] DNA from fecal samples was extracted using a bacterial DNA rapid extraction kit produced by Ark Biosafety Technology Co., Ltd. 0.2 g of fecal sample was added to a centrifuge tube, 220 μL of Buffer STE, 30 μL of Lysozyme and 5 μL of RNase Solution were added, vortexed to fully resuspend the bacteria, and incubated at 37°C for 40 minutes; 20 μL of Proteinase K and 250 μL of Buffer MBL were added to the lysate, vortexed to mix thoroughly, and incubated at 70°C for 15 minutes; 250 μL of anhydrous ethanol was added to the lysate or supernatant; vortexed for 20 seconds; gDNA Extraction Mini Columns were loaded into a 2 ml Collection Tube, and the supernatant was transferred to the column; centrifuged at 10,000 g for 1 minute; the filtrate was discarded and the column was loaded back into the collection tube; 500 μL of Buffer diluted with anhydrous ethanol was added Add Buffer W1A to the column; centrifuge at 10,000 g for 30 seconds; discard the filtrate and put the column back into the collection tube; add 600 μL of Buffer W2A diluted with anhydrous ethanol to the column, centrifuge at 10,000 g for 30 seconds, discard the filtrate, put the column back into the collection tube, and repeat the washing twice; centrifuge the empty column at 13,000 g for 2 minutes; transfer the column to a new 1.5 ml centrifuge tube and add 50 μL of Buffer EB to the center of the column membrane; leave at room temperature for 5 minutes, centrifuge at 13,000 g for 1 minute to obtain genomic DNA; use Thermo NanoDrop One to detect the integrity, purity and concentration of DNA.

[0134] (2) PCR amplification and product electrophoresis detection

[0135] Using genomic DNA as a template, PCR amplification was performed using specific primers with barcodes. The primers corresponded to the region. The primers for the 16SV1-V9 region are shown in Table 1:

[0136] Table 1

[0137] 27F 5'-AGRGTTYGATYMTGGCTCAG-3' 1492R 5'-RGYTACCTTGTTACGACTT-3'

[0138] The PCR reaction system is shown in Table 2:

[0139] Table 2

[0140] Reagent name dose Q5 25μL Primer-F (10 μM) 5μL Primer-R (10 μM) DNA 5μL DNA 2.5-50ng Nuclease-free water Add to 50μL

[0141] PCR reaction conditions are shown in Table 3:

[0142] Table 3

[0143]

[0144]

[0145] The PCR of each sample was repeated three times, and the PCR products of the same sample were mixed; the fragment length of the PCR product was detected by 1-2% agarose gel electrophoresis; the fragment length and concentration of the PCR product were detected.

[0146] (3) Pooling and gel cutting and purification

[0147] GeneTools Analysis Software, Version 4.03.05.0, SynGene was used to compare the concentrations of PCR products. The volume of each sample was calculated according to the principle of equal mass to mix the PCR products. The HiPure Gel Pure DNA Mini Kit produced by Shanghai Maigen Biotechnology Co., Ltd. was used to recover the PCR mixed product, and the target DNA fragment was eluted with TE buffer.

[0148] (4) Library construction and sequencing

[0149] Quality control and cleanup of starting DNA: Before library construction, measure DNA concentration using a Qubit fluorometer to assess the quantity and size distribution of starting DNA. Measure the DNA concentration of each sample and clean using a 1.3X SMRTbell magnetic column.

[0150] End repair and end addition A: Transfer to a new microcentrifuge tube, add 46 μL of sample, then add 8 μL of repair buffer, 4 μL of end repair mixture, and 2 μL of DNA repair mixture in sequence, vortex to mix, centrifuge in a microcentrifuge to collect the liquid, and set the program to run. The program is shown in Table 4:

[0151] Table 4

[0152] step time temperature 1 30 minutes 37℃ 2 5 minutes 65℃ 3 Keep 4℃

[0153] Connector connection and cleaning: first add 4μL SMRTbell adapter solution, then add 30μL connection mixture and 1μL connection enhancer in sequence, vortex mix, centrifuge to collect the liquid, set the program to run, use SMRTbell purification beads to clean after the run, and take the supernatant; the connection operation setting program is shown in Table 5:

[0154] Table 5

[0155] step time temperature 1 30 minutes 20℃ 2 Keep 4℃

[0156] Nuclease treatment and cleaning: add 5 μL of nuclease buffer and 5 μL of nuclease mixture in sequence, vortex and mix, centrifuge and collect the liquid, set the program to run, clean after the run, and take the supernatant; the nuclease treatment setting program is shown in Table 6:

[0157] Table 6

[0158] step time temperature 1 15 minutes 37℃ 2 Keep 4℃

[0159] Calculate total mass: Take a 1 μL aliquot from each tube and dilute with 9 μL elution buffer or water. Measure DNA using a Qubit fluorometer.

[0160] Library concentration quantification: Library construction is completed after the 16S amplicons are pooled and concentrated;

[0161] Sequencing: The constructed 16S amplicon library was sequenced using the PacBio Sequel II platform.

[0162] (5) Performing data analysis on the stool samples, including the following steps:

[0163] Step 1: OTU clustering and species annotation

[0164] OTU clustering: All Clean Tags of all samples were clustered using usearch software. By default, the sequences were clustered into OTUs (Operational Taxonomic Units) with a consistency of 97%, and one OTU was considered to represent one species. The sequence with the highest frequency of occurrence was used as the representative sequence of each OTU for subsequent annotation.

[0165] Chimera and singleton removal: remove chimera and singleton sequences during clustering.

[0166] Representative sequence species annotation: The assign_taxonomy.py script in Qiime was used to compare the representative sequence of each OTU after removing chimeras and singletons with the Silva database using RDP Classifier to obtain species annotation information.

[0167] Step 2: Species composition analysis

[0168] R software was used to count the relative abundance of species at the phylum, class, order, family, genus, and species levels. KRONA software was used to visualize the species annotation results of a single sample, and GraPhlAn software was used to obtain a single sample OTU annotation circle diagram based on GraPhlAn.

[0169] Step 3: Alpha diversity analysis

[0170] Alpha diversity index statistics: Based on the OTU abundance table, QIIME (v1.9.1) was used to calculate six diversity indices: chao1, PD_whole_tree, observed_species, Shannon, Simpson, and dominance.

[0171] Rarefaction curve: Based on the OTU abundance table, QIIME (v1.9.1) was used to calculate the rarefaction curves of eight diversity indices, including chao1, PD_whole_tree, observed_species, Shannon, Simpson, dominance, Good's coverage, and Faith's PD.

[0172] Rank Abundance curve: Rank Abundance calculation is performed based on the OTU abundance table.

[0173] Step 4: Beta diversity analysis

[0174] The Bray-Curtis, Weighted Unifrac and Unweighted Unifrac distances were calculated according to the OTU abundance information of the samples. Based on the above distance matrix, NMDS non-metric multidimensional scaling analysis, PCoA principal coordinate analysis and UPGMA non-weighted group average cluster analysis were performed.

[0175] Sample distance heatmap analysis: The vegan software of R software was used to combine the Bray-Curtis, WeightedUnifrac and Unweighted Unifrac distance algorithms and the hclust function for heatmap cluster analysis.

[0176] Cluster analysis: Based on the OTU abundance table and the beta diversity distance matrix, the UPGMA—Unweighted Pair-group Method with Arithmetic Mean cluster analysis method was used to construct a cluster tree of the samples.

[0177] Step 5: Analysis of differences between sample groups

[0178] Significance analysis of community structure differences among groups: Anosim, MRPP, Adonis and Amova were performed using the anosim function, mrpp function, adonis function and Amova of the R software vegan and pegas packages.

[0179] LEfSe analysis: Based on the homogenized abundance table OTU_table of each species level, LEfse software was used to perform significant difference analysis of species between groups. First, the non-parametric factorial Kruskal-Wallis sum-rank test was used, then the grouped Wilcoxon rank sum test was used, and finally the linear discriminant analysis LDA was used, that is, LDA Score, and the screening value of LDA Score was set to 2.

[0180] Step 6: Species Interaction Network Analysis

[0181] Collinearity network analysis: Based on the OTU abundance table, R software was used to perform collinearity network analysis on the species abundance information among different samples.

[0182] The sequencing analysis results are as follows Figure 2 As shown, the abundance of Blautia obeum in the enteric bacteria was increased in the healthy control group compared with the nontuberculous mycobacterial disease group NTM.

[0183] Experimental Example 1:

[0184] The present invention also provides a method of conducting three follow-up surveys on the non-tuberculous mycobacterial disease group NTM in combination with clinical follow-up surveys, with each follow-up survey being conducted at an interval of 2 weeks, sampling the feces of patients with non-tuberculous mycobacterial disease and comparing them with the feces of healthy subjects to analyze the abundance of Blautia obeum intestinal bacteria, such as Figure 3 As shown in the figure, compared with the healthy control group HC, the abundance of Blautiaobeum-ovate enterobacteria in patients with non-tuberculous mycobacterial disease in the first follow-up F1 and the second follow-up F2 was lower. However, as the patient's condition stabilized, the abundance of Blautia obeum-ovate enterobacteria in patients with non-tuberculous mycobacterial disease in the second follow-up F2 was higher than that in patients with non-tuberculous mycobacterial disease in the first follow-up F1, and the abundance of Blautia obeum-ovate enterobacteria in F3 at the third follow-up was comparable to that in the healthy group HC, or even higher than that in the healthy group HC. Therefore, Blautia obeum-ovate enterobacteria is conducive to the recovery and stability of non-tuberculous mycobacterial disease.

[0185] Experimental Example 2:

[0186] The present invention also provides an application of intestinal flora in treating non-tuberculous mycobacterial diseases, comprising the following steps:

[0187] (1) Preparation of mouse materials: 8-week-old female Balb / C mice were collected in 4 cages, with 5 mice in each cage. Each cage was divided into 4 groups, with a total of 20 mice.

[0188] (2) Preparation of infection strains: Take one strain of Mycobacterium abscessus ATCC19977, which is a non-tuberculous mycobacterium, and culture the strain to the logarithmic phase in 5 ml of Middlebrook 7H9 liquid medium containing 10% OADC at 37°C. Grind the bacteria to 1 McFarland unit, about 1*10 7 / ml, 10mg / ml colony forming unit CFU / ml, original solution infection, according to 20μL per mouse, a total of 35 mice, prepare 0.4ml ground bacteria turbidity to a concentration of 1*10 7 / ml, and 10mg / ml of infection bacterial solution for infection.

[0189] (3) Nasal drip infection:

[0190] Anesthetize the mouse with isoflurane as the anesthetic, making sure the mouse is fully anesthetized and unresponsive to pain. Using a medium pipette tip, take 20 μL of bacterial solution. Place the end of the pipette at the opening of one nostril and slowly expel the bacterial solution from the top. Make sure the mouse inhales the forming droplets. If not, stop adding drops until it completely inhales the droplets. After the inhalation is complete, wait for the mouse to recover for 5 to 10 minutes.

[0191] (4) The Balb / C mice in group 1 were selected as the background group and were killed one day after abscess infection.

[0192] (5) Drug treatment after infection:

[0193] Blank control group: The second group of Balb / C mice were selected as the control group. The mice were given medication every day after infection, with 0.2 ml / mice of normal saline, 15 mg / kg, for 14 consecutive days, and then the mice were killed after 14 days.

[0194] Blautia obeum-Ovulate Blautia group: The 3rd group of Balb / C mice were selected as the experimental group. The mice were given 0.2 ml / mice, 15 mg / kg, 0.5 mg / kg / day Blautia obeum daily after infection for 14 consecutive days and then killed.

[0195] Clarithromycin treatment group: Group 4 Balb / C mice were selected as the experimental group. The mice were given 0.2 ml / mice, 15 mg / kg, and 0.5 mg / kg / day clarithromycin daily after infection for 14 consecutive days and then killed.

[0196] (6) Tissue specimen collection and processing:

[0197] Tissue specimen collection and processing were carried out in the P2 laboratory. After 14 days, the mice were killed by cervical dislocation, immersed in 75% ethanol for disinfection, and the epidermis was torn open after fixation to separate the complete lung and spleen tissues;

[0198] The left lung tissue was taken for pathological sectioning: after rinsing with PBS, it was fixed in 4% PFA at 4°C overnight, sealed with a parafilm to ensure bacterial inactivation, and after external disinfection, HE and acid-fast staining were performed;

[0199] Take the right lung tissue and all spleen tissues for CFU: take the right lung tissue and all spleen tissues respectively and place them in 1ml centrifuge tubes for tissue homogenization, add 1ml PBS, grind and break the tissues thoroughly, take 100ul stock solution for serial dilution, and dilute the lung homogenate to 10 -4 , take 10 -2 , 10 -3 , 10 -4 Dilution tube, each 100ul liquid is coated on three 7H10 plates; use 200μL, 10μL pipettes, and surgical instruments are forceps and scissors; spleen tissue homogenate is diluted to 10 -3 , take 10 -1 , 10 -2 , 10 -3 Dilution tubes, 100ul of each liquid was coated on three 7H10 plates, all were cultured at 37°C, CFU was counted after 5 days, and the experimental materials were destroyed after obtaining the CFU results.

[0200] Mouse lung tissue sections Figure 4 As shown, in mice infected with nontuberculous mycobacterial lung disease, the lung tissue damage was more severe in the saline group compared with the Blautia obeum group and the clarithromycin treatment group, while treatment with Blautia obeum and clarithromycin could alleviate the lung tissue damage. Therefore, Blautiaobeum should be used to treat nontuberculous mycobacterial lung disease.

[0201] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

[0202] The preferred embodiments of the present invention disclosed above are only used to help explain the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to only specific implementation methods. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. A method for analyzing and identifying intestinal flora, characterized in that: The analytical identification method comprises the following steps: (1) DNA extraction from stool samples; (2) PCR amplification and product electrophoresis detection: PCR amplification is performed using genomic DNA as a template; the length of the PCR product is detected by electrophoresis; (3) Pooling and gel purification: Determine the concentration of PCR products and mix the PCR products; (4) Library construction and sequencing: follow the steps of starting DNA quality control and purification, end repair and end A addition, adapter ligation and cleaning, nuclease treatment and cleaning, total mass calculation, library concentration quantification and sequencing; (5) Performing data analysis on the stool samples, including the following steps: Step 1: OTU clustering and species annotation; Step 2: Species composition analysis; Step 3: Alpha diversity analysis; Step 4: Beta diversity analysis; Step 5: Analysis of differences among sample groups; Step 6: Species interaction network analysis.

2. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (1), 0.1-0.2 g of fecal sample is taken into a centrifuge tube, 220 μL of Buffer STE, 30 μL Lysozyme and 5 μL RNase Solution are added thereto, the bacteria are fully resuspended by vortexing, and the mixture is incubated at 37°C for 30-40 minutes; 20 μL of Proteinase K and 250 μL of Buffer MBL are added to the lysate, the mixture is fully inverted and vortexed for 15-20 seconds, and the mixture is incubated at 70°C for 10-15 minutes; 250 μL of anhydrous ethanol is added to the lysate or supernatant; the mixture is vortexed to mix; the gDNA Extraction Mini Columns are loaded into a 2 ml Collection Tube, and the supernatant is transferred to the column; the mixture is centrifuged at 10,000 g for 1 minute; the filtrate is discarded, and the column is loaded back into the collection tube; 500 μL of Buffer D diluted with anhydrous ethanol is added; Add Buffer W1A to the column; centrifuge at 10,000 g for 30 seconds; discard the filtrate and put the column back into the collection tube; add 600 μL of Buffer W2A diluted with anhydrous ethanol to the column, centrifuge at 10,000 g for 30 seconds, discard the filtrate, put the column back into the collection tube, and repeat the washing twice; centrifuge the empty column at 13,000 g for 2 minutes; transfer the column to a new 1.5 ml centrifuge tube, add 50-100 μL Buffer EB to the center of the column membrane; let it stand at room temperature for 2-5 minutes, and centrifuge at 13,000 g for 1 minute to obtain genomic DNA; use Thermo NanoDrop One to detect the integrity, purity and concentration of the DNA.

3. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (2), specific primers with barcodes are used for PCR amplification. The primers correspond to the regions. The primers for the 16S V1-V9 region are shown in Table 1: Table 1 The PCR reaction system is shown in Table 2: Table 2 PCR reaction conditions are shown in Table 3: Table 3 4. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (2), the PCR of each sample is repeated three times, and the PCR products of the same sample are mixed; and the fragment length of the PCR product is detected by 1-2% agarose gel electrophoresis.

5. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (3), the concentration of the PCR product is measured using GeneTools Analysis Software, Version 4.03.05.0, SynGene; The volume of each sample was calculated according to the equal mass principle to mix the PCR products. The HiPure Gel Pure DNA Mini Kit produced by Shanghai Maigen Biotechnology Co., Ltd. was used to recover the PCR mixed product, and the target DNA fragment was eluted with TE buffer.

6. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: The operation in step (4) is as follows: Quality control and cleanup of starting DNA: Before library construction, evaluate the quantity and size distribution of starting DNA, measure the DNA concentration of each sample using a Qubit fluorometer, and clean it using 1.3X SMRTbell clean magnetic columns; End repair and end addition A: transfer to a new microcentrifuge tube, add 46 μL sample and then add 8 μL repair buffer, 4 μL end repair mixture, 2 μL DNA repair mixture, vortex to mix, centrifuge in a microcentrifuge to collect the liquid and set the program to run; Connector connection and cleaning: first add the adapter solution, then add the connection mixture and connection enhancer in sequence, vortex mix, centrifuge to collect the liquid, set the program to run, use SMRTbell purification beads to wash after the run, and take the supernatant; Nuclease treatment and cleaning: add nuclease buffer and nuclease mixture in sequence, vortex mix, centrifuge to collect liquid, set the program to run, use SMRTbell purification beads for cleaning after the run, and take the supernatant; Calculate total mass: Take a 1 μL aliquot from each tube and dilute with 9 μL elution buffer or water. Measure DNA using a Qubit fluorometer. Library concentration quantification: Library construction is completed after the 16S amplicons are pooled and concentrated; Sequencing: The constructed 16S amplicon library was sequenced using the PacBio Sequel II platform.

7. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (4) of library construction and sequencing, end repair and end A addition, a 60 μL system is prepared, 46 μL of sample, 8 μL of repair buffer, 4 μL of end repair mixture and 2 μL of DNA repair mixture are added, and the setting program is shown in Table 4: Table 4 When connecting and cleaning the connector, first add 4 μL of SMRTbell adapter solution, then add 30 μL of connection mixture and 1 μL of connection enhancer in sequence. The operation setting program is shown in Table 5: Table 5 During nuclease treatment and washing, add 5 μL of nuclease buffer and 5 μL of nuclease mixture. The setting program is shown in Table 6: Table 6 。 8. The method for analyzing and identifying intestinal flora according to claim 1, characterized in that: In the step (5) of stool sample data analysis, the operation steps are as follows: Step 1: OTU clustering and species annotation OTU clustering: All Clean Tags of all samples were clustered using usearch software. By default, the sequences were clustered into OTUs (Operational Taxonomic Units) with a consistency of 97%. It was assumed that one OTU represented one species, and the sequence with the highest frequency was used as the representative sequence of each OTU for subsequent annotation. Chimera singleton removal: remove chimera and singleton sequences during clustering; Representative sequence species annotation: The assign_taxonomy.py script in Qiime was used to compare the representative sequence of each OTU after removing chimeras and singletons with the Silva database using RDP Classifier to obtain species annotation information; Step 2: Species composition analysis R software was used to calculate the relative abundance of species at the phylum, class, order, family, genus, and species levels; KRONA software was used to visualize the species annotation results of a single sample, and GraPhlAn software was used to obtain a single sample OTU annotation circle map based on GraPhlAn; Step 3: Alpha diversity analysis Alpha diversity index statistics: Based on the OTU abundance table, QIIME v1.9.1 was used to calculate six diversity indices: chao1, PD_whole_tree, observed_species, Shannon, Simpson, and dominance; Rarefaction curve: Based on the OTU abundance table, QIIME v1.9.1 was used to calculate the rarefaction curves of eight diversity indices, including chao1, PD_whole_tree, observed_species, Shannon, Simpson, dominance, Good's coverage, and Faith's PD. Rank Abundance curve: Rank Abundance calculation based on OTU abundance table; Step 4: Beta diversity analysis Bray-Curtis, Weighted Unifrac, and Unweighted Unifrac distances were calculated based on the OTU abundance information of the samples. Based on the above distance matrix, NMDS non-metric multidimensional scaling analysis, PCoA principal coordinate analysis, and UPGMA non-weighted group average cluster analysis were performed; Sample distance heatmap analysis: The vegan software of R software was used to combine the Bray-Curtis, Weighted Unifrac and Unweighted Unifrac distance algorithms and the hclust function for heatmap cluster analysis; Cluster analysis: Based on the OTU abundance table and the beta diversity distance matrix, the UPGMA—Unweighted Pair-group Method with Arithmetic Mean cluster analysis method was used to construct a cluster tree of the samples; Step 5: Analysis of differences between sample groups Significance analysis of community structure differences among groups: Anosim, MRPP, Adonis and Amova were performed using the anosim function, mrpp function, adonis function and Amova of the R software vegan and pegas packages; LEfSe analysis: Based on the homogenized abundance table OTU_table of each species level, LEfse software was used to perform significant difference analysis of species between groups. First, non-parametric factorial Kruskal-Wallis sum-ranktest was used for detection, then grouped Wilcoxon rank sum test was used, and finally linear discriminant analysis LDA was used, that is, LDA Score. The screening value of LDA Score was set to 2 for difference analysis between sample groups. Step 6: Species Interaction Network Analysis Collinearity network analysis: Based on the OTU abundance table, R software was used to perform collinearity network analysis on the species abundance information among different samples.

9. Use of the intestinal flora obtained by the analysis and identification method according to any one of claims 1 to 8 in the treatment of nontuberculous mycobacterial diseases.